罗格列酮干预对HSC-T6细胞增殖及细胞PPARγ和HO-1 mRNA水平的影响*

doi:10.3969/j.issn.1672-5069.2022.02.004

摘要/Abstract

摘要： 目的探讨罗格列酮(RGZ)干预对HSC-T6细胞增殖及对细胞过氧化物酶体增殖物激活受体γ(PPARγ)和血红素加氧酶1(HO-1)mRNA水平的影响。方法将HSC-T6细胞分为对照组、RGZ干预组和RGZ联合HO-1抑制剂ZnPP-IX处理组,采用四甲基偶氮唑盐(MTT)法检测细胞活力,使用流式细胞仪检测细胞凋亡,采用Real-time PCR法检测细胞PPARγ和HO-1 mRNA水平,采用Western Blot法检测细胞纤维化相关因子蛋白表达。结果 RGZ处理组细胞增殖A值为(0.6±0.1),显著低于对照组(1.0±0.1),细胞增殖活性降低了38.4%(P<0.05),而RGZ联合ZnPP-IX处理组为(0.8±0.1),比对照组细胞增殖活性降低了17.2%(P<0.05),但显著高于RGZ处理组(P<0.05);RGZ干预组细胞凋亡率显著高于对照组(P<0.05),而RGZ联合ZnPP-IX干预组细胞凋亡率显著低于RGZ组(P<0.05);RGZ干预组细胞PPARγ和HO-1 mRNA水平分别为(2.0±0.2)和(3.7±0.4),显著高于对照组[分别为(1.0±0.1)和(1.0±0.1),P<0.05],而RGZ联合ZnPP-IX处理组 HO-1 mRNA水平为(2.9±0.4),显著低于RGZ处理组(P<0.05);RGZ处理组细胞α-SMA、COLⅠ、COLⅢ和TGF-β1蛋白表达显著低于对照组,而RGZ联合ZnPP-IX处理组显著高于RGZ处理组(P<0.05)。结论 RGZ干预可显著抑制HSC-T6细胞增殖,促进其凋亡,发挥抗肝纤维化作用,其机制可能与抑制了细胞PPARγ和HO-1 mRNA水平有关。

关键词: HSC-T6细胞, 罗格列酮, 细胞增殖, 凋亡, 过氧化物酶体增殖物激活受体γ, 血红素加氧酶1, 体外

Abstract: Objective The aim of this study was to investigate the effects of rosiglitazone (RGZ) on cell proliferation and peroxisome proliferator-activated receptor γ (PPARγ) and heme oxygenase 1 (HO-1) levels in HSC-T6 cells in vitro. Methods The HSC-T6 cells were divided into control, RGZ- and RGZ and ZnPP-IX ( a HO-1 antagonist) combination-intervened groups (n=8), and the cell viability was detected by methyl thiazolyl tetrazolium (MTT) and the cell apoptosis was detected by flow cytometry. The cell PPARγ and HO-1 mRNA levels were detected by Real-time PCR, and the cell fibrosis-related protein expressions were detected by Western blot. Results The proliferation activity (A value) of HSC-T6 cells in RGZ-intervened group was (0.6±0.1), 38.4% decreased compared with (1.0±0.1) in the control (P<0.05), while it was (0.8±0.1) in RGZ and ZnPP-IX combination-intervened group, 17.2% decreased compared with in control group (P<0.05), but significantly increased compared with RGZ-intervened group (P<0.05); the apoptosis rate in RGZ-intervened group significantly higher than that in the control group (P<0.05), and the apoptosis rate in RGZ and ZnPP-IX combination-intervened group was significantly lower than that in RGZ-treated group (P<0.05). Conclusion RGZ intervention could significantly inhibit the proliferation and promote apoptosis of HSC-T6 cells in vitro, which might be related to the down-regulation of PPARγ and HO-1 mRNA levels.

Key words: HSC-T6 cells, Rosiglitazone, Cell proliferation, Apoptosis, Peroxisome proliferator-activated receptor γ, Heme oxygenase 1, In vitro

时扣荣, 顾伟鹰, 刘娟, 罗兰, 翟巧利, 范伟. 罗格列酮干预对HSC-T6细胞增殖及细胞PPARγ和HO-1 mRNA水平的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 165-169.

Shi Kourong, Gu Weiying, Liu Juan, et al. Effects of rosiglitazone on cell proliferation and PPARγ and HO-1 mRNA levels in HSC-T6 cells in vitro[J]. Journal of Practical Hepatology, 2022, 25(2): 165-169.

参考文献

[1] Kuo LM, Chen PJ, Sung PJ, et al. The bioactive extract of pinnigorgia sp. induces apoptosis of hepatic stellate cells via ROS-ERK/JNK-Caspase-3 signaling. Mar Drugs, 2018, 16(1):19-32.
[2] Zhu J, Luo Z, Pan Y, et al. H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-β signaling in both hepatic stellate cells and hepatocytes. J Cell Physiol, 2019, 234(6):9698-9710.
[3] Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: are we approaching success? J Clin Transl Hepatol, 2020, 8(2):222-229.
[4] Dewidar B, Meyer C, Dooley S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells, 2019, 8(11):1419-1454.
[5] Mahmoud AM, Hozayen WG, Hasan IH, et al. Umbelliferone ameliorates CCl4-induced liver fibrosis in rats by upregulating PPARγ and attenuating oxidative stress, inflammation, and TGF-β1/Smad3 signaling. Inflammation, 2019, 42(3):1103-1116.
[6] Xu W, Hu X, Qi X, et al. Vitamin D ameliorates angiotensin II-induced human endothelial progenitor cell injury via the PPAR-γ/HO-1 pathway. J Vasc Res, 2019, 56(1):17-27.
[7] Zhi SC, Chen SZ, Li YY, et al. Rosiglitazone inhibits activation of hepatic stellate cells via up-regulating micro-RNA-124-3p to alleviate hepatic fibrosis. Dig Dis Sci, 2019, 64(6):1560-1570.
[8] Ullah A, Wang K, Wu P, et al. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation. Int J Nanomedicine, 2019, 14(1):2927-2944.
[9] Fan Y, Du Z, Steib CJ, et al. Effect of SEPT6 on the biological behavior of hepatic stellate cells and liver fibrosis in rats and its mechanism. Lab Invest, 2019, 99(1):17-36.
[10] Zhang XL, Chen ZN, Huang QF, et al. Methyl helicterate inhibits hepatic stellate cell activation through modulation of apoptosis and autophagy. Cell Physiol Biochem, 2018, 51(2):897-908.
[11] 潘高峰,傅茂英,郜玉峰.内质网应激与肝纤维化关系研究进展.实用肝脏病杂志,2018,21(6):169-172.
[12] Xu X, Wang J, Jiang H, et al. Rosiglitazone induces apoptosis on human bladder cancer 5637 and T24 cell lines. Int J Clin Exp Pathol, 2017, 10(10):10197-10204.
[13] 周达,王晶,李冰航,等.脯氨酰寡肽酶抑制剂体外对HSCs凋亡、增殖和肝纤维化相关基因表达的影响.实用肝脏病杂志,2018,21(3):72-76.
[14] Liu X, Xu J, Rosenthal S, etal. Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology, 2020, 158(6):1728-1744.
[15] 俞富祥,马乃箐,陈世钻,等.罗格列酮通过微小RNA-124-3p调节HSCs活性.中华实验外科杂志,2020,37(4):775-775.
[16] Nakamura K, Kageyama S, Yue S, et al. Heme oxygenase-1 regulates sirtuin-1-autophagy pathway in liver transplantation: from mouse to human. Am J Transplant, 2018, 18(5):1110-1121.
[17] 杨慧,张丽,张晓倩,等.血晶素通过调控血红素加氧酶-1/核转录因子-κB的表达抗肝纤维化.中华肝脏病杂志,2018,26(9):654-659.
[18] Bellner L, Lebovics NB, Rubinstein R, et al. Heme oxygenase-1 upregulation: a novel approach in the treatment of cardiovascular disease. Antioxid Redox Signal, 2020, 32(14):1045-1060.
[19] Li S, Fujino M, Takahara T, et al. Protective role of heme oxygenase-1 in fatty liver ischemia-reperfusion injury. Med Mol Morphol, 2019, 52(2):61-72.
[20] Krönke G, Kadl A, Ikonomu E, et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol, 2007, 27(6):1276-1282.
[21] Yang H, Zhao LF, Zhao ZF, et al. Heme oxygenase-1 prevents liver fibrosis in rats by regulating the expression of PPARγ and NF-κB. World J Gastroenterol, 2012, 18(14):1680-1688.
[22] 杨慧,赵龙凤,张丽,等.罗格列酮调控PPARγ/HO-1的表达抑制HSCs增殖.中华肝脏病杂志,2020,28(5):410-415.

罗格列酮干预对HSC-T6细胞增殖及细胞PPARγ和HO-1 mRNA水平的影响^*

Effects of rosiglitazone on cell proliferation and PPARγ and HO-1 mRNA levels in HSC-T6 cells in vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	寇卜心, 柴梦音, 豆双双, 庞丽君, 陈德喜, 刘晓霓. p53凋亡刺激蛋白2基因肝脏条件性敲除小鼠的构建和鉴定^*[J]. 实用肝脏病杂志, 2022, 25(2): 170-173.
[2]	陈卫兵, 王小红, 刘芳. 基因1b型不同准种株丙型肝炎病毒核心蛋白对HepG2细胞生物学行为的影响^*[J]. 实用肝脏病杂志, 2022, 25(1): 13-16.
[3]	李亚萍, 翟嵩, 王媛, 邓江, 吴凤萍, 王沐淇, 贾晓黎, 李梅, 党双锁. 咖啡酸苯乙基酯缓解L02细胞脂毒性机制研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 786-789.
[4]	李经纬, 王子璇, 王梦雨, 黄瑞贤, 信丰智, 范建高, 汪保灿. 小檗碱靶向HDAC/H3K9ac/KLF4抑制棕榈酸诱导的HepG2脂肪变性体外实验研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 790-794.
[5]	沈镇扬, 王俊俊, 陆伦根, 蔡晓波. CDE饮食诱导慢性肝损伤小鼠肝组织YAP信号对肝祖细胞增殖的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 795-798.
[6]	吴伟杰, 陈源文, 丁雯瑾, 范建高. 体外脂肪变L02细胞Notch家族和脂质代谢变化研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 653-656.
[7]	田安然, 徐瑞瑞, 胡平平, 李毓雯, 朱传龙. 人EFTUD2基因靶向小分子化合物筛选细胞模型的建立^*[J]. 实用肝脏病杂志, 2021, 24(4): 472-475.
[8]	彭婕, 李弼民, 雷宇鹏. 四氯化碳诱导的肝纤维化小鼠肝组织和HSC-T6细胞NOX4基因及其蛋白表达的变化[J]. 实用肝脏病杂志, 2021, 24(3): 319-322.
[9]	王江丽, 裴凌燕, 贺晶晶, 李岚, 袁佳健, 夏莉婷, 崔雯. 血清PTX3和sTWEAK预测失代偿期乙型肝炎肝硬化患者死亡临床价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 236-239.
[10]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[11]	吴刚, 陈训军, 张万里, 李芬. 二氢姜黄素体外处理BRL-3A细胞对细胞凋亡通路的影响[J]. 实用肝脏病杂志, 2020, 23(5): 622-625.
[12]	马艳华, 黄芬, 王文尖. 紫草素对HepG2细胞增殖、凋亡和PI3K/Akt/NF-κB信号通路蛋白表达的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 471-475.
[13]	汪可, 崔现平, 刘丽娟, 支庆江, 姜文营. 蓝莓花青素干预肝硬化大鼠肝组织凋亡蛋白表达的变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 480-483.
[14]	庞丽君,石英,郭向华,乔录新,时红林,王珊珊,刘凯. 稳定表达HBx的人肝细胞系7702的建立[J]. 实用肝脏病杂志, 2020, 23(3): 320-323.
[15]	吴鹏波,宋琪,俞媛洁,郭一天,饶倩,柴红,谭诗云. 姜黄素对非酒精性脂肪肝细胞模型保护作用以及机制研究[J]. 实用肝脏病杂志, 2020, 23(3): 324-327.